Below is an overview of SynAct Pharma’s history in brief. SynAct Pharma ApS was formed in 2012. SynAct Pharma AB, the Group’s parent company, was formed in April 2016.


  • SynAct Pharma ApS is founded by Dr. Thomas Jonassen and starts operations based on acquired intellectual property rights and assets from Action Pharma A/S after Action Pharma A/S’s largest asset AP214 was sold to Abbvie Inc.
  • On November 8, the Extraordinary General Meeting will be held in SynAct. The MEETING approves the Board of Directors’ resolution regarding a directed and rights issue.


  • SynAct Pharma concludes toxicological, safety pharmacological and metabolism studies.
  • Scientific article regarding “Mode of Action” for AP1189 is published.
  • Patents are approved in Europe (patents in the US were approved in 2011).


  • SynAct Pharma AB is formed.
  • SynAct Pharma will receive approximately SEK 12.7 million through a private placement before issue costs.
  • SynAct Pharma will receive approximately SEK 32.3 million before issue costs through a new share issue prior to listing on AktieTorget.
  • SynAct Pharma’s share is listed on AktieTorget.
  • SynAct Pharma finalises commitments to funding from Seed Fund CAPNOVA through one-off payment.
  • SynAct Pharma submits the application for the start of a phase I clinical trial to the French Medicines Agency.
  • Dr Torbjørn Bjerke joins SynAct Pharma BoD as Chairman
  • Dr Thomas Jonassen joins SynAct Pharma BoD


  • Start of phase I clinical study with AP1189.
  • Start of preparation for phase IIa clinical study with AP1189.
  • Initiates pre-clinical studies in other indications.


  • Rights issue of SEK 22.4 million for expanded development program for AP1189.


  • Recruitment and dosing of patients in phase IIa clinical study with the drug candidate AP1189 in patients with active
    2019 arthritis begins.
  • The issue of approximately SEK 30 million is carried out.
  • Dr. John Haurum joins SynAct Pharma BoD
  • Dr. Terje Kalland joins SynAct Pharma BoD


  • SynAct Pharma investigates AP1189 in patients with COVID-19 and nephrotic syndrome.
  • SynAct Pharma received approximately SEK 32.4 million in warrants of series TO 2.
  • SynAct Pharma publishes positive interim data from the Phase 2 study with AP1189 in rheumatoid arthritis.
  • Uli Hacksell joins SynAct Pharma BoD


  • SynAct Pharma carries out a directed share issue of SEK 80 million
  • SynAct Pharma publishes positive data from the Phase 2 study with AP1189 in COVID-19.
  • Marina Bozilenko joins SynAct Pharma BoD